KR20190025863A - Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same - Google Patents
Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same Download PDFInfo
- Publication number
- KR20190025863A KR20190025863A KR1020190023207A KR20190023207A KR20190025863A KR 20190025863 A KR20190025863 A KR 20190025863A KR 1020190023207 A KR1020190023207 A KR 1020190023207A KR 20190023207 A KR20190023207 A KR 20190023207A KR 20190025863 A KR20190025863 A KR 20190025863A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- leaves
- tree
- skin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims description 29
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 35
- 240000000249 Morus alba Species 0.000 claims abstract description 33
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 13
- 230000009467 reduction Effects 0.000 claims abstract description 11
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 241000124033 Salix Species 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000010422 painting Methods 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 206010003645 Atopy Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000003251 Pruritus Diseases 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims description 8
- 240000005809 Prunus persica Species 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 229940100573 methylpropanediol Drugs 0.000 claims description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 241000646858 Salix arbusculoides Species 0.000 claims description 7
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 7
- 230000007803 itching Effects 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012267 brine Substances 0.000 claims description 4
- 238000001354 calcination Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
- 241000411851 herbal medicine Species 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000037307 sensitive skin Effects 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 3
- 241001164575 Salix koreensis Species 0.000 abstract description 2
- 244000046101 Sophora japonica Species 0.000 abstract description 2
- 235000010586 Sophora japonica Nutrition 0.000 abstract description 2
- 235000011446 Amygdalus persica Nutrition 0.000 abstract 1
- 235000011158 Prunus mume Nutrition 0.000 abstract 1
- 244000018795 Prunus mume Species 0.000 abstract 1
- 230000036572 transepidermal water loss Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 46
- 238000012360 testing method Methods 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 239000012676 herbal extract Substances 0.000 description 9
- -1 nitrile glycosides Chemical class 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 244000293610 Morus bombycis Species 0.000 description 3
- 235000006721 Morus bombycis Nutrition 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 101150072278 Tslp gene Proteins 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000218213 Morus <angiosperm> Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VHQQPFLOGSTQPC-UHFFFAOYSA-N pentatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC VHQQPFLOGSTQPC-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N triacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 101710128038 Hyaluronan synthase Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000301123 Morus cathayana Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- YDLYQMBWCWFRAI-UHFFFAOYSA-N n-Hexatriacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- OLTHARGIAFTREU-UHFFFAOYSA-N triacontane Natural products CCCCCCCCCCCCCCCCCCCCC(C)CCCCCCCC OLTHARGIAFTREU-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 생약 추출물을 포함하는 화장료 또는 약학 조성물 및 그의 제조방법에 관한 것으로, 더욱 상세하게는 복수의 종류이 혼합된 생약 추출물을 포함하고 추출물 제조시 전처리를 도입하여 피부 보습, 피부장벽 강화, 항염 등의 효능을 갖는 생약 추출물을 포함하는 화장료 또는 약학 조성물 및 그의 제조방법에 관한 것이다.The present invention relates to a cosmetic or pharmaceutical composition containing a herbal extract and a method for producing the same, and more particularly, to a cosmetic or a pharmaceutical composition containing a herbal extract mixed with a plurality of kinds and introducing a pretreatment in the production of an extract to provide skin moisturizing, And a pharmaceutical composition and a method for producing the same.
인체의 가장 큰 기관으로서 전체 인체 부피의 약 16%를 차지하고 있는 피부는 외부 환경과 직접 접해 있으면서, 인체 안으로 침입하려는 치명적인 많은 유해인자 예를 들면, 온도, 습도, 먼지, 자외선 등으로부터 인체를 보호하는 중요한 보호막 역할을 한다. 그러나 영유아 또는 민감성 성인들은 각종 오염물질, 강한 자외선, 스트레스 등으로 쉽게 피부 세포들이 손상을 입게 되고, 회복되는 시간도 오래 소요된다. 최근에는 홍반, 부종, 여드름, 가려움 등의 피부 자극을 호소하는 사람들이 증가하고 있는 추세며, 이로 인해 각종 자극원에 의한 피부 자극 및 염증을 감소시키고 현대인의 피부 부작용을 줄일 수 있는 항염증 및 진정효과가 우수한 물질을 개발하는 것이 절실히 요구되고 있다.The skin, which is the largest organ of the human body, occupies about 16% of the entire human body volume. It is directly contacted with the external environment, and protects the human body from many harmful factors that intrude into the human body such as temperature, humidity, dust, It plays an important protective role. However, infants or sensitive adults are easily damaged by various pollutants, strong ultraviolet rays, stress, etc., and it takes time to recover. In recent years, there have been an increasing number of people who complain of skin irritation such as erythema, edema, acne, and itch, thereby reducing skin irritation and inflammation caused by various irritants and reducing anti-inflammatory and sedative It is urgently required to develop a substance having an excellent effect.
민감한 현대인의 가장 큰 피부 고민 중 하나가 아토피 증상이다. 이러한 아토피 피부염의 증상은 심한 가려움증을 가지며 급성기에는 피부가 가렵고, 붉어지거나 붓고 좁쌀처럼 돋아 오르거나 작은 물집이 잡히고, 딱지가 앉는다. 만성기에는 가렵고 피부가 딱딱해지거나 두꺼워지거나 줄이 가거나 쌀가루 같은 비늘이 앉거나 검어지거나 또는 희게 탈색되는 모양을 보인다. 대개 아토피 피부염은 흔히 태열이라 부르는 영아기 습진으로부터 시작한다. 현재 사용하고 있는 치료약 중 스테로이드제는 크게 소염작용과 면역억제 작용이 우수하지만 부작용에 대한 우려가 있다. 장기간 바르면 바른 부위의 피부가 위축될 수 있으며, 피부색소가 적어지고 세균의 감염이 생기며, 여드름이 돋고 피부가 얇아질 수 있다. 또한 심한 경우에는 호르몬에 의한 전신 증상이 나타날 수 있다. 아토피 피부염의 발병연령이 5세 이전의 유아기에 흔하므로 스테로이드제를 사용할 경우, 호르몬 농도가 아주 적은 스테로이드 연고를 단기간에만 꼭 필요할 때 한꺼번에 많은 양을 바르기보다는 적은 양을 자주 바르는 것이 좋다.One of the biggest skin troubles of sensitive modern man is atopic symptoms. Symptoms of these atopic dermatitis are severe itching. In acute phase, the skin is itchy, reddish, swollen, sprouting up like small rice, or catching small blisters, and the scabs sit. The chronic period is itchy, and the skin becomes hard, thick, streaked, scaly like rice flour, satiated, blackened or whitened. Atopic dermatitis usually begins with an infantile eczema, often called a fever. Among steroids currently in use, steroids are highly effective in anti-inflammatory and immunosuppressive actions, but there are concerns about side effects. If applied for a long time, the skin of the right area can be shrunk, the skin pigmentation is reduced, the infection of the germ can occur, the acne may grow and the skin may become thinner. In severe cases, systemic symptoms due to hormones may occur. Since the age of onset of atopic dermatitis is common in infancy before the age of 5, it is recommended to use a small amount of steroids, rather than a lot of one at a time, when the steroid is used only for a short period of time.
아토피성 피부염은 그 자체보다 가려워 긁다가 생기는 2차성 세균감염이 더 무서운 병이다. 아토피 환자의 피부는 장기간 긁고 건조해진 결과로 세균감염이 꼭 따라온다. 아토피 환자의 90% 이상이 포도상구균에 감염되어 있는데 이 균은 환자가 가려움을 참지 못해 긁어서 생기기도 하지만 최근의 보고에 의하면 이 세균의 외독소가 우리 몸의 면역체계를 자극하여 알레르기를 일으키는 화학물질을 나오게 하여 아토피를 악화시킨다고 한다. 따라서 아토피의 치료에는 적절한 항생물질의 사용이 필수적이다. Atopic dermatitis is a more frightening disease with secondary bacterial infections that are more itchy than scratching itself. The skin of atopic patients comes with bacterial infections as a result of long-term rubbing and drying. More than 90% of patients with atopic disease are infected with Staphylococcus aureus, which can be caused by scratching the patient's itch. However, recent reports indicate that the bacteria 's exotoxin stimulates the body' s immune system, causing allergic chemicals It is said that it makes the atopy worse. Therefore, the use of appropriate antibiotics is essential for the treatment of atopy.
하지만 스테로이드제의 효과 이면에는 부작용에 대한 우려가 있기 때문에 최근에는 천연물 제제에 대한 연구가 활발히 진행되고 있다. 천연물로 조성된 제제는 부작용이 적고, 그 작용이 일반적으로 온화하고 지속적이며 생분해성이 높고 환경 친화적이다. However, since there is a fear of adverse side effects of steroid drugs, studies on natural drug preparations have been actively conducted recently. Preparations made from natural products have few side effects and their action is generally mild, persistent, biodegradable and environmentally friendly.
민감성 피부에 대한 천연물 제제의 예로서, 백급, 자소, 에키나시아 및 발효대두 추출물을 포함하는 아토피 피부의 치유 개선용 화장료 조성물, 길경, 드름, 연교, 치자, 황백, 황금, 황련, 지황, 작약, 천궁, 당귀, 시호, 박하, 우방자 및 천화분으로 구성된 생약추출물을 잎새버섯 균사체 또는 잎새버섯 균사체의 전 배양액을 혼합하여 배양하고, 이 배양액으로부터 잎새버섯 균사체를 제거한 후, 수득된 여과액을 유효성분으로 함유하는 보습, 피부자극 완화, 아토피 개선효과 및 항염효과 등의 피부개선에 우수한 효과를 가지는 발효 생약 추출물을 함유하는 피부 외용제 조성물 등이 공지되어 있다. Examples of natural product preparations for sensitive skin include cosmetic compositions for improving healing of atopic skin including white wool, barley, Echinacea, and fermented soybean extract, a cosmetic composition for improving healing of atopic skin, The present invention relates to a method for the production of a herbal composition, which comprises culturing a crude herb extract comprising a herbal extract, Angelica keiskei koidz A composition for external application for skin containing a fermented herbal extract having an excellent effect on skin improvement such as moisturizing, skin irritation alleviation, atopic improvement, and anti-inflammatory effect.
그러나 아직까지도 민감한 피부에 대한 치료제의 필수 항목인 보습효과, 항염, 가려움증 완화 등을 제공하면서도 부작용이 없는 천연 제제의 개발이 미미한 상태이며 이에 대한 연구가 필요한 실정이다.However, the development of a natural formulation which does not have side effects while providing moisturizing effect, anti-inflammation and itching relief, which are essential elements of a therapeutic agent for sensitive skin, is insufficient and research is needed.
본 발명의 목적은 피부에 대한 자극 없이 경피 수분 손실 감소, 피부 붉은기 완화 등 피부 진정 효과가 우수하고, 피부 온도 저하, 피부 보습개선, 항염 효과를 나타내어 민감한 피부에 사용하기에 매우 적합한 생약 추출물을 포함하는 화장료 또는 약학 조성물을 제공하는 데 있다.It is an object of the present invention to provide a herbal medicine extract which is excellent in skin soothing effects such as reduction of transdermal water loss and skin redness without irritation to the skin and exhibits skin temperature lowering, To provide a cosmetic or pharmaceutical composition containing the same.
본 발명의 다른 목적은 생약 추출물을 제조함에 있어서 최적의 생약 조합을 갖는 혼합 추출물을 포함하는 화장료 또는 약학 조성물을 제조하며, 전통 포제법 중 염자법을 도입하여 다양한 피부 문제의 개선 효과를 극대화하는 데 있다.Another object of the present invention is to prepare a cosmetic composition or a pharmaceutical composition containing a mixed extract having an optimal combination of herbal medicine in the production of a herbal medicine extract and to maximize the improvement effect of various skin problems by introducing a dyeing method in a conventional herbicidal process have.
본 발명의 일 측면에 따르면, According to an aspect of the present invention,
복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 화장료 조성물이 제공된다.Peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And an extract of a mixture containing willow bark; as an active ingredient.
상기 혼합물은 염자 처리된 혼합물일 수 있다.The mixture may be a chlorinated mixture.
상기 염자 처리는 소금물에 재료를 침지한 후 덖음 과정을 거친 것일 수 있다.The chlorine treatment may be a process in which the material is immersed in salt water and then subjected to scouring.
상기 덖음 과정은 80 내지 120℃에서 덖는 것일 수 있다.The quenching may be carried out at 80 to 120 ° C.
상기 덖음 과정은 20분 내지 40분 동안 수행될 수 있다.The calcination process may be performed for 20 minutes to 40 minutes.
상기 혼합 추출물은, 복숭아나무 잎 100중량부에 대하여, 뽕나무 잎 10 내지 40000중량부; 회화나무 뿌리 10 내지 20000중량부; 매화나무 열매 0.5 내지 5000중량부; 및 버드나무 껍질 10 내지 30000중량부;를 포함할 수 있다.The mixed extract may contain 10 to 40,000 parts by weight of mulberry leaves per 100 parts by weight of peach tree leaves; 10 to 20,000 parts by weight of a tree root; From 0.5 to 5000 parts by weight of plum blossom; And 10 to 30,000 parts by weight of willow bark.
상기 혼합물의 추출물은 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 및 헥산 중에서 선택된 1종 이상의 추출용매에 의해 추출된 것일 수 있다.The extract of the mixture may contain one or more extracts selected from the group consisting of purified water, glycerin, butyleneglycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, And may be one extracted with a solvent.
상기 화장료 조성물은 피부 수분 개선용, 피부 보습 증진용, 피부 진정용, 항염, 아토피 개선용, 가려움증 개선용, 및 피부 온도 감소용 중 1종 이상의 용도를 가질 수 있다.The cosmetic composition may have at least one of application for skin moisture improvement, skin moisturizing enhancement, skin soothing, anti-inflammation, atopic amelioration, itching improvement, and skin temperature reduction.
상기 혼합물의 추출물은 상기 화장료 조성물 전체 중량에 대하여 0.0001 내지 90중량%의 함량으로 포함될 수 있다.The extract of the mixture may be contained in an amount of 0.0001 to 90% by weight based on the total weight of the cosmetic composition.
본 발명의 다른 하나의 측면에 따르면, According to another aspect of the present invention,
복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료의 성분을 추출하는 단계를 포함하는 화장료 조성물의 제조방법이 제공된다.Extracting a component of a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, painting tree roots, plum blossom, and willow bark.
상기 화장료 조성물의 제조방법은, (a) 복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료를 세척하여 세척된 재료를 준비하는 단계; (b) 상기 세척된 재료를 소금물에 침지시킨 후, 덖음 과정을 거침으로써 염자 처리된 재료를 준비하는 단계; (c) 상기 염자 처리된 재료를 분쇄한 후, 추출용매로 추출하여 여과액을 수득하는 단계; 및 (d) 상기 여과액을 농축 후 건조시켜 건조된 추출분말을 제조하는 단계;를 포함할 수 있다.(A) preparing a washed material by washing a material containing at least one selected from a peach tree leaf, a mulberry leaf, a painting tree root, a plum tree fruit, and a willow bark; (b) immersing the washed material in salt water and then subjecting the washed material to a salt treatment to prepare a chlorinated material; (c) pulverizing the chlorinated material and extracting it with an extraction solvent to obtain a filtrate; And (d) concentrating and drying the filtrate to prepare a dried extract powder.
단계 (a)의 상기 재료는, 복숭아나무 잎 100중량부에 대하여, 뽕나무 잎 10 내지 40000중량부; 회화나무 뿌리 10 내지 20000중량부; 매화나무 열매 0.5 내지 5000중량부; 및 버드나무 껍질 10 내지 30000중량부;를 포함할 수 있다.Wherein the material of step (a) comprises, relative to 100 parts by weight of peach tree leaves, 10 to 40,000 parts by weight of mulberry leaves; 10 to 20,000 parts by weight of a tree root; From 0.5 to 5000 parts by weight of plum blossom; And 10 to 30,000 parts by weight of willow bark.
단계 (b)의 상기 소금물은 2% 내지 4% 농도일 수 있다.The brine of step (b) may be in a concentration of 2% to 4%.
단계 (c)는 80 내지 120℃에서 20 내지 40분 동안 덖음으로써 수행될 수 있다.Step (c) can be carried out by stirring at 80 to 120 캜 for 20 to 40 minutes.
단계 (d)의 상기 추출용매는 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 및 헥산 중에서 선택된 1종 이상일 수 있다.The extraction solvent of step (d) is selected from the group consisting of purified water, glycerin, butylene glycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, It may be more than one kind.
단계 (e) 이후, 상기 추출분말을 추출용매에 용해시켜 추출액을 제조하는 단계;를 추가로 수행할 수 있다.After step (e), the extraction powder may be dissolved in an extraction solvent to prepare an extract.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 항염 약학 조성물이 제공된다.Peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And an extract of a mixture containing willow bark; as an active ingredient, an anti-inflammatory pharmaceutical composition is provided.
또한, 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 아토피 개선 또는 치료용 약학 조성물이 제공된다.Also, peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And an extract of a mixture comprising willow bark; as an active ingredient, a pharmaceutical composition for improving or treating atopy.
또한, 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 가려움증 개선 또는 치료용 약학 조성물이 제공된다.Also, peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And an extract of a mixture containing willow bark; as an active ingredient, a pharmaceutical composition for improving or treating itching is provided.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료의 성분을 추출하는 단계를 포함하는 약학 조성물의 제조방법이 제공된다.Extracting a component of a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, painting tree roots, plum fruit, and willow bark.
본 발명의 화장료 또는 약학 조성물은 다섯 가지의 생약 추출물을 포함하여 피부에 대한 자극 없이 경피 수분 손실 감소, 피부 붉은기 완화 등 피부 진정 효과가 우수하고, 피부 온도 저하, 피부 보습개선, 항염 효과를 나타내어 민감한 피부에 사용하기에 매우 적합하다.The cosmetic or pharmaceutical composition of the present invention includes five herbal medicine extracts, and is excellent in skin sedative effects such as reduction of transdermal water loss, alleviation of skin redness without irritation to the skin, lowering of skin temperature, improvement of skin moisturizing effect and anti- It is very suitable for use on sensitive skin.
또한, 본 발명의 화장료 또는 약학 조성물의 제조방법은 생약 추출물을 제조함에 있어서 최적의 생약 조합을 갖는 혼합 추출물을 제조하며, 전통 포제법 중 염자법을 도입하여 다양한 피부 문제의 개선 효과를 극대화할 수 있다.In addition, the method of producing a cosmetic composition or a pharmaceutical composition of the present invention can produce a mixed extract having an optimal combination of herbal medicine in the production of herbal extracts, and can maximize the improvement effect of various skin problems by introducing a salt- have.
도 1은 시험예 1의 세포 이동 효과 분석 결과를 나타낸 것이다.
도 2는 시험예 2의 수분 함량 개선 효과 분석 결과를 나타낸 것이다.
도 3은 시험예 3의 보습 개선 효과 분석 결과를 나타낸 것이다.
도 4는 시험예 4의 항염 효과 분석 결과를 나타낸 것이다.
도 5는 시험예 5의 아토피 억제 효과 분석 결과를 나타낸 것이다.
도 6은 시험예 6의 피부 진정 효과에서 경피수분손실량의 분석 결과를 나타낸 것이다.
도 7은 시험예 6의 피부 진정 효과에서 붉은기 감소효과의 분석 결과를 나타낸 것이다.
도 8은 시험예 7의 피부 온도 감소 효과 분석 결과를 나타낸 것이다.Fig. 1 shows the cell migration effect analysis result of Test Example 1. Fig.
Fig. 2 shows the results of the water content improving effect analysis of Test Example 2. Fig.
Fig. 3 shows the results of the moisturizing and improving effect analysis of Test Example 3. Fig.
4 shows the results of the analysis of the anti-inflammatory effect of Test Example 4. Fig.
Fig. 5 shows the result of the atopy inhibitory effect analysis of Test Example 5. Fig.
Fig. 6 shows the results of analysis of transdermal water loss in the skin soothing effect of Test Example 6. Fig.
Fig. 7 shows the analysis result of the redness reduction effect in the skin soothing effect of Test Example 6. Fig.
Fig. 8 shows the result of the skin temperature reduction effect test of Test Example 7. Fig.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
본 출원에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 구성요소, 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 구성요소, 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.
The terminology used in this application is used only to describe a specific embodiment and is not intended to limit the invention. The singular expressions include plural expressions unless the context clearly dictates otherwise. In the present application, the terms "comprises" or "having" are used to specify that a feature, a number, a step, an element, or a combination thereof is to be described, But do not preclude the presence or addition of steps, components, or combinations thereof.
이하, 본 발명의 화장료 조성물에 대해 설명하도록 한다.Hereinafter, the cosmetic composition of the present invention will be described.
본 발명의 화장료 조성물은 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함한다.The cosmetic composition of the present invention comprises peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And willow bark; as an active ingredient.
상기 혼합물은 염자 처리된 것을 사용하는 것이 바람직하다.It is preferable that the mixture is subjected to a chlorine treatment.
상기 염자 처리는 소금물에 재료를 침지한 후 덖음 과정을 거친 것을 의미한다.The chlorine treatment means that the saltwater is dipped in the salt water and then subjected to a drenching process.
상기 덖음 과정은 80 내지 120℃에서 20분 내지 40분 동안 수행되는 것이 바람직하다.The calcination is preferably performed at 80 to 120 ° C for 20 minutes to 40 minutes.
상기 혼합 추출물은, 복숭아나무 잎 100중량부에 대하여, 뽕나무 잎 10 내지 40000중량부; 회화나무 뿌리 10 내지 20000중량부; 매화나무 열매 0.5 내지 5000중량부; 및 버드나무 껍질 10 내지 30000중량부;를 포함할 수 있다.The mixed extract may contain 10 to 40,000 parts by weight of mulberry leaves per 100 parts by weight of peach tree leaves; 10 to 20,000 parts by weight of a tree root; From 0.5 to 5000 parts by weight of plum blossom; And 10 to 30,000 parts by weight of willow bark.
상기 복숭아나무 잎에는 니트릴 배당체를 함유하고 있고 타닌질이 0.07~0.2% 함유되어 있고, 아스파라긴산, 라이코펜 등이 풍부하다. The peach tree leaves contain nitrile glycosides, 0.07-0.2% tannin, and are rich in aspartic acid, lycopene, and the like.
상기 혼합 추출물에는 복숭아나무의 부위 중 잎 부위를 포함하는 것이 바람직하나, 경우에 따라 다른 부위를 적용할 수도 있다. 복숭아나무 꽃에는 켐페롤과 그 배당체, 3염기산과 디옥시1염기산이 함유되어 있으며, 씨에는 에물신이 약 30%, 아미그달린이 약 1.5% 함유되어 있으며, 나무껍질에는 나린게닌, 트리아콘탄, 펜타트리아콘탄 등이 있고, 기름 40 내지 50%(주성분은 올레인, 팔미틴, 스테아린)가 함유되어 있다. 동의치료에서 꽃을 이뇨제, 센 설사약으로 변비치료에 쓰이며, 민간에서는 잎이 붙은 가지를 가마에 넣고 달인 액으로 건포, 습진에 이용하였다. It is preferable that the mixed extract includes a leaf part of a part of a peach tree, but other parts may be applied depending on the case. Peach tree flowers contain chemperol and its glycosides, tribasic acid and dioxybasic acid. The seeds contain about 30% fetishin and about 1.5% of amigalline. The bark contains naringenin, triacontane, And pentatriacontane, and it contains 40 to 50% of oil (main components are olein, palmitin, stearin). Flowers are used for diuretic therapy and constipation therapy in the treatment of bronchial asthma, and in the private sector, leafy branches are put into a kiln and used for manure and eczema.
상기 매화나무의 열매는 매실이라고 불리고, 열매는 둥글고 여물면 노란색을 띤다. 열매산에는 레몬산, 사과산, 포도산, 호박산, 시토스테롤, 올레아놀산, 세틸알코올, 씨에는 아미그달린이 있으며, 선열매는 레몬산의 원료로도 사용하고, 마른 열매에는 레몬산 19%, 사과산 1.5%가 들어 있다. 동의치료에서 청량성 수렴약, 설사 멎이약, 열내림약, 기침약, 가래약으로 쓴다(약초의 성분과 이용, 일월서각, 1999, 358). 매실에는 히스페리딘, 카테킨 산이 함유되어 피부 항염에 효과적일 수 있다.The fruit of the plum tree is called plum, and the fruit is round and yellow when yellow. There are lemon, malic, vine, succinic acid, sitosterol, oleic acid, cetyl alcohol and seed amidgalin in the fruit acid, and the raw fruit is used as a raw material of lemon acid. Dry fruit contains 19% of lemon acid and 1.5% of malic acid. In migraine treatment, it is used as a calming concentrate, diarrhea, fever, cough medicine, and phlegm (herbal ingredients and use, January, 1999, 358). The plum contains hysperidin and catechin acid, which can be effective for skin inflammation.
뽕나무(상지)는 뽕나무속 식물의 여린 가지를 말린 것으로 뽕나무속 식물로는 뽕나무(Morus alba, Linne), 처진 뽕나무(Morus alba for. Peldulls DIPPEL), 산 뽕나무(Morus bombycis, Koidzumi), 꼬리 뽕나무(Morus bombycis var. Caudatifolia), 섬 뽕나무(Morus bombycis var. maritima KOIDZ), 가새 뽕나무(Morus tiliaefolia, Makino)가 있으며, 이들은 낙엽활엽성의 교목으로 한국의 대부분 지역에 걸쳐 수평적으로 분포하며, 산골 마을 부근이나 산기슭에 자생한다. 통상적으로 상지는 약간 쓴맛이 나며 소염, 이뇨, 강장, 발한 및 풍을 제거하는 효능이 있어, 오래전부터 한약재로 널리 쓰이고 있다. 특히 뽕나무 잎은 폴리페놀이 풍부하여 높은 항산화 효과를 가지며, 피부장벽 구성요소의 중요한 성분 중 하나인 지질이 풍부하여 피부 장벽 강화에 효과적일 수 있다. Morus alba, Linne, Morus alba for Peldulls DIPPEL, Morus bombycis, Koidzumi, and Mulberry trees are the most common species of mulberry trees. Morus bombycis var. Caudatifolia, Morus bombycis var. Maritima KOIDZ, Morus tiliaefolia, Makino, which are deciduous broad - leaved arboreous trees distributed horizontally throughout most of Korea, It grows in the foot of the mountain. The upper limbs are usually bitter and have the efficacy to remove inflammation, diuretic, tongue, sweating and wind, and have been widely used as herbal medicines for a long time. Especially, mulberry leaves are rich in polyphenols and have high antioxidative effect. They are effective in strengthening the skin barrier by abundant lipid, which is one of the important components of the skin barrier component.
회화나무(Sophora Japonica L)는 콩과에 속하며, 높이 25m 안팍으로 한국, 일본, 중국 등지에 분포한다. 회화나무의 뿌리에는 퀘르세틴(Quercetin)이 풍부하여 피부 보습에 효과적이다(Colloids and Surfaces B: Biointerfaces, Volume 123, 1 November 2014, Pages 778-786). Painted wood (Sophora Japonica L) belongs to the soybean family, and is distributed in Korea, Japan, and China, with a height of 25m. Quercetin is abundant in the roots of painting trees and is effective in moisturizing the skin (Colloids and Surfaces B: Biointerfaces,
버드나무(Salix koreensis Andersson)는 버들 또는 뚝 버들이라고도 하며 껍질에는 타닌질 3~10%, 플라본, 아스코르부산, 배당체 살리신 등이 있다. 살리신은 약 5%까지 포함되어 있으며 효소에 의하여 살리게닌과 포도당으로 분해된다. 버드나무는 아스피린의 주요작용 성분과 비슷한 성분(Salicyl)을 가지고 있어서 열을 내리게 하고 염증과 통증을 완화하는 작용을 한다. 버드나무 껍질에는 살리실산이 풍부하기 때문에 피부 항염에 효과적일 수 있다. The willow (Salix koreensis Andersson) is also known as willow or weeping will, with 3 ~ 10% of tannin in the skin, flavon, ascorbic acid, salicylic acid. Salicin contains up to 5% and is degraded to saline and glucose by enzymes. Willow has a component (salicyl) that is similar to the main active ingredient of aspirin, so it acts to relieve fever and relieve inflammation and pain. Willow bark is rich in salicylic acid, so it can be effective for skin inflammation.
상기 혼합물의 추출물은 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 헥산 등의 추출용매에 의해 추출될 수 있으나, 본 발명의 범위가 여기에 한정되지 않으며, 식물 재료의 추출에 사용될 수 있는 다양한 추출용매를 사용할 수 있다.The extract of the mixture is extracted with an extraction solvent such as purified water, glycerin, butyleneglycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, However, the scope of the present invention is not limited thereto, and various extraction solvents that can be used for extraction of plant material can be used.
상기 화장료 조성물은 피부 수분 개선용, 피부 보습 증진용, 피부 진정용, 항염, 아토피 개선용, 가려움증 개선용, 피부 온도 감소용 등의 용도로 사용될 수 있다.The cosmetic composition can be used for skin moisture improvement, skin moisturizing enhancement, skin soothing, anti-inflammation, atopic amelioration, itching improvement, skin temperature reduction and the like.
상기 화장료 조성물은 혼합물의 추출물이거나 상기 혼합물의 추출액을 진공, 농축 후 동결 건조시킨 분말이거나, 상기 분말을 추출용매와 배합한 배합물일 수 있다.The cosmetic composition may be an extract of the mixture, a powder obtained by freeze-drying the extract of the mixture in vacuo, concentration, or a combination of the powder and an extraction solvent.
상기 혼합물의 추출물은 바람직하게는 화장료 조성물의 총 중량에 대하여 0.0001 내지 90중량%의 함량으로 포함될 수 있다. 왜냐하면, 혼합물의 추출물 함량이 0.0001중량% 미만인 경우에는 피부 진정 효과가 나타나기 어렵고, 90중량% 이상인 경우에는 제형 상의 안정성이 저하될 수 있다.
The extract of the mixture may preferably be contained in an amount of 0.0001 to 90% by weight based on the total weight of the cosmetic composition. This is because when the content of the extract is less than 0.0001% by weight, the skin soothing effect is hardly exhibited, and when it is more than 90% by weight, the stability on the formulation may be lowered.
이하, 본 발명의 화장료 조성물의 제조방법에 대해 설명하도록 한다.Hereinafter, the method for producing the cosmetic composition of the present invention will be described.
본 발명의 화장료 조성물의 제조방법은 복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료의 성분을 추출하는 단계를 포함한다.The method for producing a cosmetic composition of the present invention comprises extracting a component of a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, tree roots, plum blossom, and willow bark.
구체적으로는 먼저, 복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료를 세척하여 세척된 재료를 준비한다(단계 a).Specifically, first, the washed material is prepared by washing a material including at least one selected from peach tree leaves, mulberry leaves, roots of painting trees, fruit of plum, and willow bark (step a).
상기 재료는 복숭아나무 잎 100중량부에 대하여, 뽕나무 잎 10 내지 40000중량부; 회화나무 뿌리 10 내지 20000중량부; 매화나무 열매 0.5 내지 5000중량부; 및 버드나무 껍질 10 내지 30000중량부;를 포함한다.Wherein the material is selected from the group consisting of 10 to 40,000 parts by weight of mulberry leaves, 10 to 20,000 parts by weight of a tree root; From 0.5 to 5000 parts by weight of plum blossom; And 10 to 30,000 parts by weight of willow bark.
이후, 상기 세척된 재료를 소금물에 침지시킨 후, 덖음 과정을 거침으로써 염자 처리된 재료를 준비한다(단계 b).Thereafter, the washed material is immersed in brine, and then a crystallization process is performed to prepare a chlorine-treated material (step b).
상기 소금물은 2% 내지 4% 농도인 것이 바람직하다.The salt water is preferably in a concentration of 2% to 4%.
덖음 과정은 80 내지 120℃에서 20 내지 40분 동안 수행하는 것이 바람직하다.The calcination is preferably carried out at 80 to 120 DEG C for 20 to 40 minutes.
이후, 상기 염자 처리된 재료를 분쇄한 후, 추출용매로 추출하여 여과액을 수득한다(단계 c).Thereafter, the seed treated material is pulverized and then extracted with an extraction solvent to obtain a filtrate (step c).
상기 혼합물의 추출물은 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 헥산 등의 추출용매에 의해 추출될 수 있고, 더욱 바람직하게는 정제수, 메칠프로판디올, 헥산디올을 사용할 수 있다. 본 발명의 범위가 여기에 한정되지 않으며, 식물 재료의 추출에 사용될 수 있는 다양한 추출용매를 사용할 수 있다.The extract of the mixture is extracted with an extraction solvent such as purified water, glycerin, butyleneglycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, And more preferably, purified water, methylpropanediol, or hexanediol can be used. The scope of the present invention is not limited thereto, and various extraction solvents that can be used for extraction of plant materials can be used.
이후, 상기 여과액을 농축 후 건조시켜 건조된 추출분말을 제조한다(단계 d).Thereafter, the filtrate is concentrated and dried to prepare dried extract powder (step d).
상기 농축은 감압 농축에 의하는 것이 바람직하고, 상기 건조는 동결 건조에 의해 수행될 수 있으나, 본 발명의 범위가 여기에 한정되지 않는다.The concentration is preferably carried out by reduced-pressure concentration, and the drying can be performed by lyophilization, but the scope of the present invention is not limited thereto.
이후, 건조된 추출분말은 추출용매에 용해시켜 추출액으로 제조할 수 있다.
Thereafter, the dried extract powder may be dissolved in an extraction solvent to prepare an extract.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 유효성분 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예를 들어서 항산화제, 안정화제, 용해화제, 비타민, 향료와 같은 통상적인 보조제, 그리고 담제를 포함한다. 본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 파우더, 비누, 계면활성제 함유 클렌징, 오일, 분말파운데이션, 유탁액 파운데이션, 왁스 파운데이션 증으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는 세안용 클렌징, 로션, 크림, 마사지 크림, 아이크림, 에센스, 젤, 팩, 스프레이, 파우더, 선크림 등의 제형으로 제조될 수 있다.The ingredients contained in the cosmetic composition of the present invention include, in addition to the above-mentioned effective ingredients, the ingredients conventionally used in cosmetic compositions, for example, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, And includes pancakes. The cosmetic composition of the present invention may be prepared in any form conventionally produced in the art and may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil , A powder foundation, an emulsion foundation, a wax foundation, etc. However, the present invention is not limited thereto. More specifically, it can be manufactured in the form of cleansing cleansing lotion, cream, massage cream, eye cream, essence, gel, pack, spray, powder, sunscreen and the like.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로 식물성유, 왁스, 전분, 셀룰로오스, 실리콘, 벤토나이트, 실리카, 산화아연 등이 이용될 수 있고, 제형이 파우더 경우에는 담체 성분으로서 락토스, 실리카, 알루미늄 히드록사이드, 칼슘 실리케이트 등의 파우더가 이용될 수 있다. 본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 글리세린, 에틸 카보네이트, 에틸 아세테이트, 프로필렌글라이콜, 부틸렌글라이콜, 1,2-헥산디올, 글리세롤 지방족 에스테르, 소르비탄 지방산 에스테르가 있다. When the formulation of the present invention is a paste, a cream or a gel, vegetable oil, wax, starch, cellulose, silicone, bentonite, silica, zinc oxide or the like may be used as a carrier component. , Aluminum hydroxide, calcium silicate and the like may be used. When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, glycerin, ethyl carbonate, ethyl acetate, propylene glycol, butyleneglycol, , 2-hexanediol, glycerol aliphatic ester, and sorbitan fatty acid ester.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올, 프로필렌글라이콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록사이드, 벤토나이트, 아가 등이 이용될 수 있다. 또한 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세치오네이트, 메칠타우레이트, 사르코시네이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세라이드, 식물성유 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.
When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol, propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, etc. may be used. Also, when the formulation is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, methyl taurate, sarcosinate, alkylamido betaine, aliphatic alcohol, Rid, vegetable oil, or ethoxylated glycerol fatty acid ester.
또한, 본 발명은 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 항염, 약학 조성물을 제공한다.The present invention also relates to a process for the production of peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And a willow bark. The present invention also provides a pharmaceutical composition comprising the extract as an active ingredient.
또한, 본 발명은 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 아토피 개선 또는 치료용 약학 조성물을 제공한다.The present invention also relates to a process for the production of peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And an extract of a mixture comprising willow bark; as an active ingredient, a pharmaceutical composition for improving or treating atopy.
또한, 본 발명은 복숭아나무 잎; 뽕나무 잎; 회화나무 뿌리; 매화나무 열매; 및 버드나무 껍질;을 포함하는 혼합물의 추출물을 유효성분으로 포함하는 가려움증 개선 또는 치료용 약학 조성물을 제공한다.The present invention also relates to a process for the production of peach tree leaves; Mulberry leaves; Painting tree roots; Plum tree fruit; And a willow bark; as an active ingredient, a pharmaceutical composition for improving or treating itching.
상기 혼합물의 추출물은 앞서 설명한 본 발명의 화장료 조성물에서와 동일하므로 상세한 내용은 그 부분을 참조하기로 한다.
The extract of the mixture is the same as that of the cosmetic composition of the present invention described above, so that details thereof will be referred to for the details.
또한, 본 발명은 복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료의 성분을 추출하는 단계를 포함하는 약학 조성물의 제조방법을 제공한다. In addition, the present invention provides a method for preparing a pharmaceutical composition comprising extracting a component of a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, nursery tree roots, plum tree fruit, and willow bark .
상기 성분을 추출하는 방법은 앞서 설명한 화장료 조성물의 제조방법에서와 동일하므로 구체적인 내용은 그 부분을 참조하기로 한다.
The method of extracting the above components is the same as that of the above-described method for producing a cosmetic composition, and therefore, the details thereof will be referred to.
본 발명의 약학 조성물은 상기 유효 성분 이외에 약학으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a flavoring agent may be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약학으로 허용 가능한 담체를 1종 이상 포함하여 약학 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약학 조성물의 제제 형태는 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 등이 될 수 있다. 예를 들어, 또한, 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The pharmaceutical form of the pharmaceutical composition may be liquid, syrup, juice, suspension, emulsion, drip agent, or the like. For example, also, if necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
본 발명의 약학 조성물은 경피 투여에 의하는 것이 바람직하다.
The pharmaceutical composition of the present invention is preferably administered by transdermal administration.
[실시예] [Example]
실시예Example 1: One: 염자A seed 처리한 생약 추출물의 제조 Manufacture of herbal extracts treated
(1) 재료 세척(1) Material cleaning
복숭아나무 잎, 매화나무 열매, 뽕나무 잎, 회화나무 뿌리, 버드나무 껍질 각각 1kg 시료로 선별하여 충분히 세척하여 재료를 준비하였다. Peach tree leaf, plum tree fruit, mulberry leaf, painting tree roots, and willow bark, respectively.
(2) 염자 처리(2) Treatment of chlorophyll
다음으로 깨끗하게 정제된 소금을 이용하여 제조된 3% 소금물 용액에 잘 혼합시킨 후 밀폐하여 3시간 동안 소금이 잘 스며들도록 방치한 후, 소금물이 완전히 흡수된 복숭아나무 잎, 매화나무 열매, 뽕나무 잎, 회화나무 뿌리, 버드나무 껍질을 약 100℃의 온도에서 30분간 덖음 과정을 거친 후 그늘에서 건조시켰다.Then, the mixture was mixed well with a 3% brine solution prepared using cleanly purified salt, and the mixture was sealed and allowed to stand for 3 hours to allow salt to penetrate. Then, peach tree leaves, plum blossom, mulberry leaves, Painted tree roots and willow bark were shaken at a temperature of about 100 ° C for 30 minutes and then dried in the shade.
(3) 생약 추출 (3) Herbal extracts
그 다음 분쇄한 후 300메시 체에 통과시켜 분쇄물을 미세하게 만들었다. 이후, 최종 농도가 60%(v/v) 에탄올 수용액이 되도록 에탄올을 첨가하여 3시간씩 2회 환류추출하고 냉침하고, 와트만(whatman) #2 여과지로 여과하였다. 여과된 추출물은 감압 농축 후 동결 건조하였다. Then, the mixture was crushed and passed through a 300-mesh sieve to finely crush the crushed material. Then, ethanol was added so that the final concentration became 60% (v / v) ethanol aqueous solution, refluxed twice for 3 hours, cooled, and filtered with
구체적으로, 감압 농축은 여과된 추출물을 로터리 감압농축기를 이용하여 농축하였으며, 농축 조건은 1,000㎖ 라운드 플라스크에 600㎖의 추출물을 넣고 700mmHg의 압력으로 50℃, 1000rpm으로 회전하면서 2시간 동안 감압 농축하였다.Specifically, the filtered extract was concentrated using a rotary vacuum concentrator, and 600 ml of the extract was placed in a 1,000 ml round-bottomed flask, and the mixture was concentrated under reduced pressure for 2 hours while rotating at 1000 rpm at a pressure of 700 mmHg .
감압 농축한 농축액은 예비동결을 수행하여 -40℃로 온도를 낮추고, -40℃로 3시간 동안 유지한 후 트랩 냉동을 통하여 -80℃까지 떨어뜨리고 진공을 20mTorr로 유지한 다음 2시간에 걸쳐 -40℃까지 다시 올린다. 그 후 -20℃로 4시간, 0℃로 1시간, 15℃로 6시간, 30℃로 2시간 유지하고 완전히 건조될 때까지 20시간으로 유지하여 동결건조된 파우더를 제조하였다.The concentrate under reduced pressure was subjected to preliminary freezing to lower the temperature to -40 ° C., maintain it at -40 ° C. for 3 hours, freeze trapped to -80 ° C., maintain the vacuum at 20 mTorr, Raise it to 40 ℃ again. Thereafter, the mixture was kept at -20 ° C for 4 hours, at 0 ° C for 1 hour, at 15 ° C for 6 hours, at 30 ° C for 2 hours, and maintained at 20 hours until completely dried to prepare a lyophilized powder.
동결건조된 파우더는 10% 메칠프로판디올, 2% 1,2-헥산디올을 이용하여 최종적으로 1%(v/v), 10%(v/v)의 농도가 되도록 용해시켜 생약추출물을 제조하였다.
The lyophilized powder was dissolved in a concentration of 1% (v / v) and 10% (v / v) using 10% methylpropanediol and 2% 1,2- .
실시예Example 2: 2: 열수Heat number 생약추출물의 제조 Preparation of herbal extracts
염자 처리를 생략한 것을 제외하고는 실시예 1과 동일한 방법으로 생약 추출물을 제조하였다.
A crude herbal extract was prepared in the same manner as in Example 1, except that the seedling treatment was omitted.
[시험예][Test Example]
시험예Test Example 1: 세포 이동( 1: cell migration ( CellCell MigrationMigration ) 효과 분석) Effect analysis
신생아 피부 섬유아 세포(HDFn cell, human dermal fibroblast neonatal cell)에 실시예 1의 1%(v/v) 추출물(염자 1), 실시예 2의 1%(v/v)추출물(DW 1)을 가하여 24시간 후 세포 이동 효과를 관찰하였다.1% (v / v) extract (Example 1) of Example 1 and 1% (v / v) extract (DW 1) of Example 2 were added to HDFn cells (human dermal fibroblast neonatal cell) And the cell migration effect was observed after 24 hours.
실시예 1에 따라 염자 처리된 생약 추출물의 세포 이동 효과를 확인하기 위하여 실시예 2의 열수 생약추출물과 비교한 광학 현미경 이미지를 도 1에 나타내었다. 도 1에 따르면, HDFn 세포에서 세포 이동 평가 결과 실시예 2의 열수 추출물에 비하여 실시예 1의 염자 처리를 추가로 수행한 추출물이 세포 이동 효과가 더욱 우수한 것으로 나타났다.
FIG. 1 shows an optical microscope image of the herbal medicine extract compared with the hydrothermal extract of Example 2 to confirm the cell migration effect of the herbicide-treated herb extract according to Example 1. According to FIG. 1, as a result of cell migration evaluation in HDFn cells, the extract obtained by further performing the dyeing treatment of Example 1 was superior to the hot-water extract of Example 2 in cell migration.
실험예Experimental Example 2: 수분 함량 개선 효과 분석 2: Analysis of water content improvement effect
인간 피부 각질형성세포에 실시예 1의 1%(v/v) 추출물(염자 1), 실시예 1의 10%(v/v) 추출물(염자 10), 실시예 2의 1%(v/v)추출물(DW 1), 실시예 2의 10%(v/v)추출물(DW 10)을 가하여 피부 수분 함량에 관여하는 아쿠아포린(AQP3) 및 히알루론산(HAS3) 합성 효소 유전자 발현율을 평가하여 그 결과를 도 2에 나타내었다. 여기서 “ra”는 레티놀을 의미한다. 도 2에 따르면, 본 발명의 생약 추출물은 피부 수분 개선에 효과적인 것으로 나타났으며, 특히, 염자 처리를 추가로 수행한 실시예 1의 생약 추출물이 아쿠아포린 및 히알루론산 합성 효소 유전자 발현율을 더욱 높이는 것으로 나타났다.
(V / v) extract (Example 1) of Example 1, 10% (v / v) extract (Example 10) of Example 1 and 1% (v / v) of Example 2 (AQP3) and hyaluronic acid (HAS3) synthase genes involved in skin moisture content were evaluated by adding the extract (DW 1) extract of Example 2 and the 10% (v / v) extract (DW 10) The results are shown in Fig. Here, "ra" means retinol. 2, the herbal medicine extract of the present invention was shown to be effective in improving the skin moisture, and in particular, the herbal medicine extract of Example 1, in which the salt treatment was further performed, further enhanced the expression of aquaporin and hyaluronic acid synthase gene appear.
실험예Experimental Example 3: 보습 개선 효과 분석 3: Analysis of moisturizing improvement effect
인간 피부 각질형성세포에 실시예 1의 1%(v/v) 추출물(염자 1), 실시예 1의 10%(v/v) 추출물(염자 10), 실시예 2의 1%(v/v)추출물(DW 1), 실시예 2의 10%(v/v)추출물(DW 10)을 가하여 피부 각질형성세포에서 각질분화에 관여하는 필라그린과 세포 간 결합력에 관여하는 클라우딘 유전자 발현율을 평가하여 그 결과를 도 3에 나타내었다. 도 3에 따르면, 피부 각질형성세포에서 각질분화에 관여하는 필라그린과 세포 간 결합력에 관여하는 클라우딘 유전자 발현율을 증가시켜 피부 장벽을 튼튼하게 하고 결과적으로 피부 보습 개선 효과를 기대할 수 있다.
(V / v) extract (Example 1) of Example 1, 10% (v / v) extract (Example 10) of Example 1 and 1% (v / v) of Example 2 ) Extracts (DW 1) and the 10% (v / v) extract (DW 10) of Example 2 were added to evaluate the expression of cladin gene involved in the keratin differentiation in papilloma and cell- The results are shown in Fig. According to FIG. 3, it is possible to increase the rate of expression of clodin gene involved in pillared green and cell-cell binding force involved in differentiation of keratinocytes in dermal keratinocytes, thereby strengthening skin barrier and consequently improving skin moisturizing effect.
실험예Experimental Example 4: 항염 효과 분석 4: Analysis of anti-inflammatory effect
인간 피부 각질형성세포에 염증 유도 물질인 Poly I:C를 처리한 후, 실시예 1의 1%(v/v) 추출물(염자 1), 실시예 1의 10%(v/v) 추출물(염자 10), 실시예 2의 1%(v/v)추출물(DW 1), 실시예 2의 10%(v/v)추출물(DW 10), 덱사메타손(항히스타민제)을 가하여 IL-8의 유전자 발현율을 평가하여 그 결과를 도 4에 나타내었다. 도 4에 따르면, 실시예 1의 추출물과 실시예 2의 10%(v/v)추출물이 종래 사용되는 항히스타민제인 덱사메타손에 비하여 항염 효과가 더 우수한 것으로 나타났다.
The human skin keratinocytes were treated with Poly I: C, an inflammation inducing substance, and then treated with 1% (v / v) extract (Example 1) of Example 1 and 10% (v / v) 8 gene expression rate by adding 1% (v / v) extract (DW 1) of Example 2, 10% (v / v) extract (DW 10) of Example 2 and dexamethasone (antihistamine) The results are shown in Fig. According to FIG. 4, the extract of Example 1 and the 10% (v / v) extract of Example 2 were superior to the conventional antihistamine dexamethasone.
실험예Experimental Example 5: 아토피 억제 효과 분석 5: Atopy inhibitory effect analysis
인간 피부 각질형성세포에 TSLP(피부에 가려움을 유도하는 화학 물질) 유도 물질인 Poly I:C 및 IL-4를 처리한 후, 실시예 1의 1%(v/v) 추출물(염자 1), 실시예 1의 10%(v/v) 추출물(염자 10), 실시예 2의 1%(v/v)추출물(DW 1), 실시예 2의 10%(v/v)추출물(DW 10), 덱사메타손(항히스타민제)을 가하여 TSLP 유전자 발현율을 측정하여 그 결과를 도 5에 나타내었다. 도 5에 따르면, 본 발명의 생약 추출물은 모두 TSLP 유전자 발현율이 약물처리를 하지 않은 실험군(+)에 비하여 낮게 나타나 아토피 억제 효과가 있는 것으로 확인되었으며, 특히 실시예 1의 10%(v/v) 추출물 처리군에서 아토피 억제 효과가 가장 우수한 것으로 나타났다.
The human skin keratinocytes were treated with Poly I: C and IL-4, which are inducers of TSLP (skin-inducing chemicals), and then treated with 1% (v / v) (V / v) extract (DW 10) of Example 1, 1% (v / v) extract (DW 1) of Example 2 and 10% , Dexamethasone (antihistamine agent) was added to measure the expression rate of TSLP gene, and the results are shown in FIG. 5, the TSLP gene expression rate of the herbal medicine extract of the present invention was lower than that of the test group (+) in which no drug treatment was performed, and it was confirmed that the TSLP gene expression was 10% (v / v) In the extract treatment group, the atopy inhibition effect was the best.
시험예Test Example 6: 피부 진정 효과 분석 6: Analysis of skin soothing effect
선정 기준에 부합하는 피험자 20명을 선별하여 피부 진정효과를 입증하기 위한 시험을 진행하였다. 먼저, 1% SLS(소듐라우레스설페이트) 용액을 피부에 첩포하여, 경피수분손실량(TEWL)과 피부 붉은기(a-value)가 증가한 부위에 실시예 1의 1%(v/v) 추출물 15㎕를 24시간씩 2회 첩포하여, 생약 추출물의 첩포 후 24시간, 48시간 경과한 시점에서의 TEWL과 a-value의 변화를 관찰하여 그 결과를 각각 도 6 및 도 7에 나타내었다. 도 6 및 도 7에 따르면, 경피수분손실량은 24시간, 48시간 경과 후 모두 대조부위에 비해 통계학적으로 유의한(p<0.05) 수준으로 크게 감소하였고, 피부 붉은기(a-value)는 시료 첩포 24시간 후 대조부위에 비해 통계학적으로 유의한(p<0.05) 수준으로 감소하여 실시예 1의 1%(v/v) 추출물이 피부 진정 효과가 우수한 것으로 나타났다.
Twenty subjects who met the selection criteria were selected and tested to demonstrate skin soothing effects. First, 1% (v / v) extract 15 of Example 1 was applied to the skin where the 1% SLS (sodium laureth sulfate) solution was applied to the skin and the area of increased transdermal water loss (TEWL) and skin- The results are shown in FIG. 6 and FIG. 7, respectively. The results are shown in FIG. 6 and FIG. 7, respectively. The results are shown in FIG. 6 and FIG. 7, respectively, after 24 hours and 48 hours after application of the herbal medicine extract. According to Figs. 6 and 7, the amount of transdermal water loss was significantly reduced to a level (p <0.05) statistically significant compared with the control site after 24 hours and 48 hours, and skin- (P < 0.05) after 24 hours of the patch compared to the control area, indicating that the 1% (v / v) extract of Example 1 was superior in skin soothing effect.
시험예Test Example 7: 피부 온도 감소 효과 분석 7: Skin temperature reduction effect analysis
피부 온도 저하 효과를 입증하기 위하여 인체 적용 시험을 진행하였다. 먼저, 선정 기준에 부합하는 피험자 21명을 선별하여 실시예 1의 1%(v/v) 추출물을 피험자 안면부에 도포하여 열화상 카메라를 사용하여 피부 온도 변화를 분석하여 그 결과를 도 8에 나타내었다. 도 8에 따르면, 시료를 도포한 부위는 시료 도포 직 후, 도포 전에 비해 통계적으로 유의한 수준(p<0.05)으로 피부 온도가 감소하여 피부 온도 감소 효과를 가지는 것으로 판단되며, 실험 결과 양쪽 볼 부위 모두 평균 2.5?의 온도 감소 효과를 나타내었다.
In order to demonstrate the effect of lowering the skin temperature, a human body application test was conducted. First, 21 subjects who matched the selection criteria were selected, and 1% (v / v) extract of Example 1 was applied to the face of the subject, and skin temperature changes were analyzed using a thermal imaging camera. The results are shown in FIG. . According to FIG. 8, it was judged that the skin-temperature reduction effect of the region where the sample was applied was decreased to a statistically significant level (p < 0.05) immediately after the application of the sample, All showed an average temperature reduction of 2.5 °.
이상, 본 발명의 실시예들에 대하여 설명하였으나, 해당 기술 분야에서 통상의 지식을 가진 자라면 특허청구범위에 기재된 본 발명의 사상으로부터 벗어나지 않는 범위 내에서, 구성 요소의 부가, 변경, 삭제 또는 추가 등에 의해 본 발명을 다양하게 수정 및 변경시킬 수 있을 것이며, 이 또한 본 발명의 권리범위 내에 포함된다고 할 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, many modifications and changes may be made by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims. The present invention can be variously modified and changed by those skilled in the art, and it is also within the scope of the present invention.
Claims (20)
상기 혼합물은 염자 처리된 혼합물인 것을 특징으로 하는 화장료 조성물.The method according to claim 1,
Wherein the mixture is a salt-treated mixture.
상기 염자 처리는 소금물에 재료를 침지한 후 덖음 과정을 거친 것을 특징으로 하는 화장료 조성물.3. The method of claim 2,
Characterized in that the salt treatment is carried out by immersing the salt in a salt water and then finishing the salt treatment.
상기 덖음 과정은 80 내지 120℃에서 덖는 것을 특징으로 하는 화장료 조성물.The method of claim 3,
Wherein the softening process is performed at 80 to 120 ° C.
상기 덖음 과정은 20분 내지 40분 동안 수행되는 것을 특징으로 하는 화장료 조성물.5. The method of claim 4,
Wherein the calcination is carried out for 20 minutes to 40 minutes.
상기 혼합 추출물은,
복숭아나무 잎 100중량부에 대하여,
뽕나무 잎 10 내지 40000중량부;
회화나무 뿌리 10 내지 20000중량부;
매화나무 열매 0.5 내지 5000중량부; 및
버드나무 껍질 10 내지 30000중량부;를 포함하는 것을 특징으로 하는 화장료 조성물.The method according to claim 1,
The above-
With respect to 100 parts by weight of peach tree leaves,
10 to 40,000 parts by weight of mulberry leaves;
10 to 20,000 parts by weight of a tree root;
From 0.5 to 5000 parts by weight of plum blossom; And
And 10 to 30,000 parts by weight of a willow bark.
상기 혼합물의 추출물은 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 및 헥산 중에서 선택된 1종 이상의 추출용매에 의해 추출된 것을 특징으로 하는 화장료 조성물.The method according to claim 1,
The extract of the mixture may contain one or more extracts selected from the group consisting of purified water, glycerin, butyleneglycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, Wherein the cosmetic composition is extracted with a solvent.
상기 화장료 조성물은 피부 수분 개선용, 피부 보습 증진용, 피부 진정용, 항염, 아토피 개선용, 가려움증 개선용, 및 피부 온도 감소용 중 1종 이상의 용도를 갖는 화장료 조성물.The method according to claim 1,
The cosmetic composition of the present invention has at least one of the following applications: skin moisturizing, skin moisturizing, skin cleansing, anti-inflammation, atopic amelioration, itching improvement and skin temperature reduction.
상기 혼합물의 추출물은 상기 화장료 조성물 전체 중량에 대하여 0.0001 내지 90중량%의 함량으로 포함되는 것을 특징으로 하는 화장료 조성물.The method according to claim 1,
Wherein the extract of the mixture is contained in an amount of 0.0001 to 90% by weight based on the total weight of the cosmetic composition.
상기 화장료 조성물의 제조방법은,
(a) 복숭아나무 잎, 뽕나무 잎, 회화나무 뿌리, 매화나무 열매, 및 버드나무 껍질 중에서 선택된 1종 이상을 포함하는 재료를 세척하여 세척된 재료를 준비하는 단계;
(b) 상기 세척된 재료를 소금물에 침지시킨 후, 덖음 과정을 거침으로써 염자 처리된 재료를 준비하는 단계;
(c) 상기 염자 처리된 재료를 분쇄한 후, 추출용매로 추출하여 여과액을 수득하는 단계; 및
(d) 상기 여과액을 농축 후 건조시켜 건조된 추출분말을 제조하는 단계;를 포함하는 것을 특징으로 하는 화장료 조성물의 제조방법.11. The method of claim 10,
The method for producing the cosmetic composition,
(a) preparing a washed material by washing a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, painting tree roots, plum blossom, and willow bark;
(b) immersing the washed material in salt water and then subjecting the washed material to a salt treatment to prepare a chlorinated material;
(c) pulverizing the chlorinated material and extracting it with an extraction solvent to obtain a filtrate; And
(d) concentrating and drying the filtrate to prepare a dried extract powder.
단계 (a)의 상기 재료는,
복숭아나무 잎 100중량부에 대하여,
뽕나무 잎 10 내지 40000중량부;
회화나무 뿌리 10 내지 20000중량부;
매화나무 열매 0.5 내지 5000중량부; 및
버드나무 껍질 10 내지 30000중량부;를 포함하는 것을 특징으로 하는 화장료 조성물의 제조방법.12. The method of claim 11,
The material of step (a)
With respect to 100 parts by weight of peach tree leaves,
10 to 40,000 parts by weight of mulberry leaves;
10 to 20,000 parts by weight of a tree root;
From 0.5 to 5000 parts by weight of plum blossom; And
And 10 to 30,000 parts by weight of a willow bark.
단계 (b)의 상기 소금물은 2% 내지 4% 농도인 것을 특징으로 하는 화장료 조성물의 제조방법.12. The method of claim 11,
Wherein the brine of step (b) is in a concentration of 2% to 4%.
단계 (c)는 80 내지 120℃에서 20 내지 40분 동안 덖음으로써 수행되는 것을 특징으로 하는 화장료 조성물의 제조방법.12. The method of claim 11,
Wherein step (c) is carried out by shaking at 80 to 120 DEG C for 20 to 40 minutes.
단계 (d)의 상기 추출용매는 정제수, 글리세린, 부틸렌글라이콜, 헥산디올, 메칠프로판디올, 프로판디올, 프로필렌글라이콜, 에탄올, 메탄올, 에틸아세테이트, 디클로로메탄, 에틸에테르, 및 헥산 중에서 선택된 1종 이상인 것을 특징으로 하는 화장료 조성물의 제조방법.12. The method of claim 11,
The extraction solvent of step (d) is selected from the group consisting of purified water, glycerin, butylene glycol, hexanediol, methylpropanediol, propanediol, propylene glycol, ethanol, methanol, ethyl acetate, dichloromethane, ethyl ether, Wherein the cosmetic composition is at least one kind of cosmetic composition.
단계 (e) 이후, 상기 추출분말을 추출용매에 용해시켜 추출액을 제조하는 단계;를 추가로 수행하는 것을 특징으로 하는 화장료 조성물의 제조방법.12. The method of claim 11,
And (e) after the step (e), dissolving the extracted powder in an extraction solvent to prepare an extract.
Extracting a component of a material comprising at least one selected from the group consisting of peach tree leaves, mulberry leaves, painting tree roots, plum blossom, and willow bark.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190023207A KR20190025863A (en) | 2019-02-27 | 2019-02-27 | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190023207A KR20190025863A (en) | 2019-02-27 | 2019-02-27 | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170077485A Division KR102025859B1 (en) | 2017-06-19 | 2017-06-19 | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190025863A true KR20190025863A (en) | 2019-03-12 |
Family
ID=65800172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190023207A Withdrawn KR20190025863A (en) | 2019-02-27 | 2019-02-27 | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190025863A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102212305B1 (en) * | 2020-04-27 | 2021-02-05 | 주식회사 더가든오브내추럴솔루션 | A cosmetic composition comprising plant extract as active ingredient, and a preparation method of thereof |
KR20230131504A (en) * | 2022-03-03 | 2023-09-14 | 코스맥스 주식회사 | Composition comprising microorganism fermented oil of traditional herbal medicines and its use for improving skin condition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100431076B1 (en) | 2003-06-16 | 2004-05-12 | 주식회사 코스메카코리아 | A cosmetic composition containing the mixture of natural plant extracts to recover atopy skin |
KR101081914B1 (en) | 2009-02-02 | 2011-11-09 | 한불화장품주식회사 | Skin-care agent containing oriental-herb extracts |
-
2019
- 2019-02-27 KR KR1020190023207A patent/KR20190025863A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100431076B1 (en) | 2003-06-16 | 2004-05-12 | 주식회사 코스메카코리아 | A cosmetic composition containing the mixture of natural plant extracts to recover atopy skin |
KR101081914B1 (en) | 2009-02-02 | 2011-11-09 | 한불화장품주식회사 | Skin-care agent containing oriental-herb extracts |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102212305B1 (en) * | 2020-04-27 | 2021-02-05 | 주식회사 더가든오브내추럴솔루션 | A cosmetic composition comprising plant extract as active ingredient, and a preparation method of thereof |
WO2021221405A1 (en) * | 2020-04-27 | 2021-11-04 | 주식회사 더가든오브내추럴솔루션 | Functional cosmetic composition comprising plant extract as active ingredient and preparation method therefor |
KR20230131504A (en) * | 2022-03-03 | 2023-09-14 | 코스맥스 주식회사 | Composition comprising microorganism fermented oil of traditional herbal medicines and its use for improving skin condition |
CN116807934A (en) * | 2022-03-03 | 2023-09-29 | 科丝美诗株式会社 | Composition of microbial fermentation oil comprising Korean medicinal material and its use in improving skin condition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101315265B1 (en) | Cosmetic composition for improving skin senescence | |
KR101566320B1 (en) | Cosmetic composition comprising an Impatiens balsamina L, Maca, Rosa multiflora Thunberg, Eryobotrya japonica and Pachyrrhizus erosus Complex-fermented extract | |
KR101284656B1 (en) | Cosmetic Composition | |
KR101829892B1 (en) | A cosmetic composition comprising fraxinus rhynchophylla extract and calystegia soldanella extract | |
KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
KR20090056521A (en) | Cosmetic composition for preventing skin aging and improving wrinkles containing rambutan and rich extract as active ingredients | |
KR102330277B1 (en) | Cosmetics composition comprising centella asiatica extracts | |
KR20130030032A (en) | Cosmetic compositions comprising extracts of hubs | |
KR101347036B1 (en) | Composition of cosmetic using natural complex extract as anti-oxidant agent | |
JPH10295325A (en) | Health food | |
KR20180138245A (en) | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR20190025863A (en) | Cosmetic or phamaceutical composition comprising herb extract and method for preparing the same | |
KR20120009554A (en) | Cosmetic composition containing herbal extracts having antioxidant and anti-allergic effects | |
KR20230081343A (en) | Hair and scalp cosmetic composition containing natural fermented extract | |
KR101889344B1 (en) | Cosmetic composition containing the complex extracts of Hibiscus Esculentus, Momordica Charantia and Morinda Citrifolia | |
KR100985228B1 (en) | Cosmetic composition using wax gourd for improving skin | |
KR101799155B1 (en) | External preparation for skin comprising extract of Traditional herb | |
KR100903827B1 (en) | Handmade herbal soap and its manufacturing method | |
CN111281844A (en) | A kind of compound natural extract light spot facial mask and preparation method thereof | |
KR20090075950A (en) | Intractable atopic dermatitis treatment composition | |
KR102303400B1 (en) | Preparation Methods of Fermentation Products Using JEJU Lava Seawater, JEJU Barley Yeast and Natural Plant and Cosmetic Compositions Having Thereof | |
KR102421800B1 (en) | Composition comprising fermented extract of Halophilic microorganism | |
KR102162917B1 (en) | Cosmetic composition comprising complex extracts of Artemisia absinthium, Belamcanda chinensis, Sedum sarmentosum, Solidago virgaurea and Actinidia polygama | |
KR102116816B1 (en) | Cosmetic composition comprising extracts of Taheebo, Dictamnus dasycarpus Turcz., Hemiptelea davidii and Melia azedarach L. for preventing and treating atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20190227 Patent event code: PA01071R01D Filing date: 20170619 Application number text: 1020170077485 |
|
PG1501 | Laying open of application | ||
PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20190524 |
|
WITB | Written withdrawal of application |